Aliases & Classifications for Adenocarcinoma

MalaCards integrated aliases for Adenocarcinoma:

Name: Adenocarcinoma 12 28 51 41 14 69
Adenocarcinomas 12

Classifications:



External Ids:

Disease Ontology 12 DOID:299
MeSH 41 D000230
NCIt 46 C2852
UMLS 69 C0001418

Summaries for Adenocarcinoma

Disease Ontology : 12 A carcinoma that has material basis in abnormally proliferating cells, derives from epithelial cells, which originate in glandular tissue.

MalaCards based summary : Adenocarcinoma, also known as adenocarcinomas, is related to papillary adenocarcinoma and mucinous adenocarcinoma. An important gene associated with Adenocarcinoma is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Abraxane and Cervarix have been mentioned in the context of this disorder. Affiliated tissues include lung, prostate and liver, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 72 Adenocarcinoma (/ˌædɪnoʊkɑːrsɪˈnoʊmə/; plural adenocarcinomas or adenocarcinomata... more...

Related Diseases for Adenocarcinoma

Diseases in the Adenocarcinoma family:

Adenocarcinoma in Situ

Diseases related to Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1201)
# Related Disease Score Top Affiliating Genes
1 papillary adenocarcinoma 34.3 CDH1 ERBB2 MUC1
2 mucinous adenocarcinoma 34.2 CDKN2A EGFR KRAS MUC1 TP53
3 tubular adenocarcinoma 34.2 CDH1 EGFR ERBB2 MUC1
4 small intestinal adenocarcinoma 34.1 BRAF CTNNB1 EGFR ERBB2 KRAS MUC1
5 signet ring cell adenocarcinoma 34.1 CDH1 CTNNB1 MUC1 TP53
6 colon adenocarcinoma 34.0 CDH1 CTNNB1 KRAS PTGS2
7 cervical adenocarcinoma 33.9 CDKN2A EGFR ERBB2 PTGS2 TP53
8 nasal cavity adenocarcinoma 33.9 CDKN2A KRAS TP53
9 pancreas adenocarcinoma 33.9 AKT1 CDH1 CDKN2A CTNNB1 EGFR KRAS
10 endometrial adenocarcinoma 33.9 CDKN2A CTNNB1 EGFR ERBB2 KRAS TP53
11 esophagus adenocarcinoma 33.8 CDKN2A ERBB2 PTGS2 TP53
12 breast adenocarcinoma 33.8 EGFR ERBB2 TP53
13 barrett's adenocarcinoma 33.8 CDKN2A ERBB2 KRAS PTGS2 TP53
14 pancreatic ductal adenocarcinoma 33.7 AKT1 CDH1 CDKN2A CTNNB1 EGFR ERBB2
15 colorectal adenocarcinoma 33.6 BRAF CDH1 CTNNB1 EGFR KRAS PTGS2
16 gastric adenocarcinoma 33.6 CDH1 CTNNB1 ERBB2 PTGS2 ROS1 SMAD4
17 bile duct adenocarcinoma 33.6 CDH1 EPCAM KRAS MUC1 TP53
18 barrett esophagus 33.5 CDH1 CDKN2A ERBB2 PTGS2 TP53
19 adenosquamous carcinoma 33.4 EGFR KRAS MUC1 TP53
20 fallopian tube endometrioid adenocarcinoma 33.4 CDKN2A ERBB2
21 pseudomyxoma peritonei 32.8 KRAS MUC1 TP53
22 colorectal adenoma 32.7 CTNNB1 KRAS PTGS2 TP53
23 cystadenocarcinoma 32.6 AKT1 MUC1 TP53
24 bile duct carcinoma 32.6 CDH1 MUC1 PTGS2 TP53
25 esophageal cancer 32.6 AKT1 CDH1 CDKN2A CTNNB1 EGFR ERBB2
26 adenoma 32.6 BRAF CTNNB1 KRAS PTGS2 SMAD4 TGFBR2
27 primary peritoneal carcinoma 32.5 EGFR ERBB2 TP53
28 lung cancer susceptibility 3 32.5 BIRC5 BRAF CDH1 CDKN2A CTNNB1 EGFR
29 renal cell carcinoma, nonpapillary 32.4 AKT1 CDH1 EGFR EPCAM KDR MUC1
30 cholangiocarcinoma 32.2 CDH1 ERBB2 KRAS MUC1 PTGS2 ROS1
31 paget disease, extramammary 32.2 ERBB2 ERBB4 MUC1
32 hidradenocarcinoma 32.0 EGFR ERBB2 TP53
33 ovarian serous carcinoma 31.9 ERBB2 KRAS PTGS2 TP53
34 gastric cancer 31.9 AKT1 CDH1 CDKN2A CTNNB1 EGFR ERBB2
35 serous cystadenocarcinoma 31.8 AKT1 BIRC5 TP53
36 prostate cancer 31.5 AKT1 BIRC5 CDH1 CTNNB1 EGFR ERBB2
37 endometrial cancer 31.5 AKT1 BRAF CDH1 CDKN2A CTNNB1 EGFR
38 pancreatic cancer 31.4 AKT1 BIRC5 CDH1 CDKN2A CTNNB1 EGFR
39 lung cancer 31.4 AKT1 BIRC5 BRAF CDH1 CDKN2A CTNNB1
40 ovarian cancer 31.2 AKT1 BIRC5 BRAF CDH1 CTNNB1 EGFR
41 bladder cancer 31.2 BIRC5 CDH1 CDKN2A EGFR ERBB2 FGFR3
42 peutz-jeghers syndrome 31.0 CTNNB1 SMAD4 TP53
43 small cell cancer of the lung 31.0 CDKN2A EGFR RB1 TP53
44 villous adenoma 30.9 BRAF KRAS MUC1
45 pleomorphic adenoma 30.8 ERBB2 MUC1 TP53
46 mature teratoma 30.8 BRAF KRAS TP53
47 familial adenomatous polyposis 30.8 CDH1 CTNNB1 KRAS PTGS2 SMAD4 TP53
48 cholecystitis 30.7 CDH1 CDKN2A MUC1 TP53
49 acinar cell carcinoma 30.6 CTNNB1 SMAD4 TP53
50 transitional cell carcinoma 30.6 CDH1 EGFR ERBB2 FGFR3 PTGS2 TP53

Graphical network of the top 20 diseases related to Adenocarcinoma:



Diseases related to Adenocarcinoma

Symptoms & Phenotypes for Adenocarcinoma

GenomeRNAi Phenotypes related to Adenocarcinoma according to GeneCards Suite gene sharing:

25 (show all 33)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.08 EGFR BRAF KRAS MUC1
2 Decreased viability GR00106-A-0 11.08 KRAS
3 Decreased viability GR00107-A-1 11.08 TGFBR2
4 Decreased viability GR00221-A-1 11.08 AKT1 CDKN2A FGFR3 EGFR KDR TGFBR2
5 Decreased viability GR00221-A-2 11.08 AKT1 FGFR3 KDR KRAS ROS1
6 Decreased viability GR00221-A-3 11.08 AKT1 CDKN2A ERBB2 FGFR3 KDR TGFBR2
7 Decreased viability GR00221-A-4 11.08 AKT1 CDKN2A ERBB2 EGFR KDR TGFBR2
8 Decreased viability GR00301-A 11.08 BRAF KRAS CDH1 ERBB4
9 Decreased viability GR00342-S-1 11.08 ERBB4 ROS1
10 Decreased viability GR00381-A-1 11.08 KRAS BRAF
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-10 10.43 FGFR3
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 10.43 TGFBR2
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.43 TGFBR2
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.43 ERBB2
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.43 KDR TGFBR2
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.43 TGFBR2
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-20 10.43 TGFBR2
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.43 AKT1
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-48 10.43 TGFBR2
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.43 KDR
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 10.43 FGFR3
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.43 AKT1 ERBB2 FGFR3 KDR TGFBR2
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 10.43 TGFBR2
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 10.43 TGFBR2
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 10.43 ERBB2
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 10.43 KDR
27 Decreased cell migration GR00055-A-1 10.11 AKT1 BRAF CTNNB1 EGFR ERBB4 FGFR3
28 Decreased viability in esophageal squamous lineage GR00235-A 10.06 BRAF CDH1 CDKN2A CTNNB1 ERBB2 FGFR3
29 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.98 CTNNB1 EGFR EPCAM ERBB2 ERBB4 FGFR3
30 Increased cell death HMECs cells GR00103-A-0 9.73 BIRC5 CTNNB1 EGFR ERBB4 TGFBR2 TP53
31 Increased cell migration GR00055-A-3 9.63 CTNNB1 EGFR ERBB4 KDR KRAS BRAF
32 Increased cell viability after pRB stimulation GR00230-A-1 9.35 AKT1 EGFR ERBB2 ERBB4 TGFBR2
33 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 BRAF KDR ROS1 SMAD4 TGFBR2

MGI Mouse Phenotypes related to Adenocarcinoma:

43 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.6 KDR KRAS PTGS2 RB1 ROS1 SMAD4
2 cardiovascular system MP:0005385 10.53 AKT1 BRAF CDH1 CDKN2A CTNNB1 EGFR
3 embryo MP:0005380 10.53 RB1 SMAD4 TGFBR2 TP53 AKT1 BIRC5
4 behavior/neurological MP:0005386 10.51 AKT1 BRAF CDKN2A CTNNB1 EPCAM ERBB2
5 endocrine/exocrine gland MP:0005379 10.5 CDKN2A CTNNB1 EGFR EPCAM ERBB2 ERBB4
6 homeostasis/metabolism MP:0005376 10.5 AKT1 BIRC5 BRAF CDH1 CDKN2A CTNNB1
7 growth/size/body region MP:0005378 10.49 CTNNB1 EGFR EPCAM ERBB2 FGFR3 KDR
8 immune system MP:0005387 10.49 AKT1 BIRC5 BRAF CDH1 CDKN2A CTNNB1
9 hematopoietic system MP:0005397 10.48 AKT1 BIRC5 BRAF CDKN2A CTNNB1 EGFR
10 digestive/alimentary MP:0005381 10.46 CDKN2A CTNNB1 EGFR EPCAM ERBB2 FGFR3
11 mortality/aging MP:0010768 10.46 AKT1 BIRC5 BRAF CDH1 CDKN2A CTNNB1
12 integument MP:0010771 10.42 AKT1 BRAF CDH1 CDKN2A CTNNB1 EGFR
13 craniofacial MP:0005382 10.4 RB1 SMAD4 TGFBR2 TP53 BRAF CTNNB1
14 nervous system MP:0003631 10.36 AKT1 BRAF CDKN2A CTNNB1 EGFR EPCAM
15 muscle MP:0005369 10.34 CDKN2A CTNNB1 EGFR ERBB2 ERBB4 KDR
16 neoplasm MP:0002006 10.32 AKT1 BRAF CDH1 CDKN2A CTNNB1 EGFR
17 normal MP:0002873 10.31 ERBB2 ERBB4 FGFR3 KDR KRAS PTGS2
18 liver/biliary system MP:0005370 10.3 SMAD4 TGFBR2 TP53 AKT1 BRAF CDKN2A
19 no phenotypic analysis MP:0003012 10.21 CDH1 CDKN2A CTNNB1 EGFR EPCAM FGFR3
20 adipose tissue MP:0005375 10.18 AKT1 BRAF EGFR PTGS2 RB1 TGFBR2
21 limbs/digits/tail MP:0005371 10.14 FGFR3 KRAS RB1 SMAD4 TP53 CTNNB1
22 hearing/vestibular/ear MP:0005377 10.13 BRAF CTNNB1 EGFR FGFR3 KRAS RB1
23 reproductive system MP:0005389 10.13 AKT1 BRAF CDH1 CDKN2A CTNNB1 EGFR
24 respiratory system MP:0005388 10 AKT1 BRAF CDKN2A CTNNB1 EGFR ERBB2
25 renal/urinary system MP:0005367 9.97 BRAF CTNNB1 EGFR FGFR3 KRAS PTGS2
26 pigmentation MP:0001186 9.91 BRAF CDKN2A CTNNB1 EGFR KRAS RB1
27 skeleton MP:0005390 9.8 KDR KRAS PTGS2 RB1 SMAD4 TGFBR2
28 vision/eye MP:0005391 9.36 BRAF CDKN2A CTNNB1 EGFR FGFR3 KDR

Drugs & Therapeutics for Adenocarcinoma

FDA approved drugs:

(show all 11)
# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Abraxane 17 45 PACLITAXEL Celgene October 2012
2
Cervarix 17 45 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
3
Cyramza 17 45 RAMUCIRUMAB Eli Lilly April 2014
4
Eloxatin 17 45 OXALIPLATIN Sanofi-aventis August 2002
5
Gardasil 17 45 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
6
Gemzar 17 45 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
7
Gilotrif 17 45 AFATINIB DIMALEATE Boehringer Ingelheim July 2013
8
Herceptin 17 45 TRASTUZUMAB Genentech October 1998
9
Iressa 17 45 GEFITINIB AstraZeneca May 2003
10
Sutent 17 45 SUNITINIB MALATE Pfizer May 2011/ January 2006
11
Taxotere 17 45 DOCETAXEL Rhone Poulenc Rorer May 1996

Drugs for Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1043)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 2767 441203 84093
2
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
4
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 95058-81-4 60750
5
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
6
Clarithromycin Approved Phase 4 81103-11-9 84029
7
Metronidazole Approved Phase 4,Phase 2,Phase 1 443-48-1 4173
8
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
9
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 2216-51-5 16666
10
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 61825-94-3 43805 6857599 5310940 9887054
11
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 7553-56-2 807
12
Cefazolin Approved Phase 4 25953-19-9 33255 656510
13
Propranolol Approved, Investigational Phase 4,Phase 2 525-66-6 4946
14
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 142217-69-4 153941
15
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2 134678-17-4 60825
16
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
17
Ethiodized oil Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 8008-53-5
18
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 284461-73-0 216239 406563
19
Coal tar Approved Phase 4,Phase 3,Phase 2,Phase 1 8007-45-2
20
Telbivudine Approved, Investigational Phase 4,Phase 1 3424-98-4 159269
21
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 198153-51-4 5360545
22
Ribavirin Approved Phase 4,Phase 3,Phase 2 36791-04-5 37542
23
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
24
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
25
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
26
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 97682-44-5, 100286-90-6 60838
27
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
28
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 169590-42-5 2662
29
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
30
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
31
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
32
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
33
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-43-4 5816
34 Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 329-65-7
35
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 56420-45-2 41867
36
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 2 142340-99-6 60871
37
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
38
Dopamine Approved Phase 4,Phase 2,Phase 1 51-61-6, 62-31-7 681
39
Nicotine Approved Phase 4,Phase 3 54-11-5 89594 942
40
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 110942-02-4, 85898-30-2
41
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
42
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 68538-85-2
43
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Phase 1 128794-94-5 5281078
44
Mycophenolic acid Approved Phase 4,Phase 2,Phase 1 24280-93-1 446541
45
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
46
Pancrelipase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
47
Zinc Approved, Investigational Phase 4,Phase 2,Phase 1 7440-66-6 32051 23994
48
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 53-03-2 5865
49
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 180288-69-1 9903
50
Iron Approved Phase 4,Phase 3,Phase 1 7439-89-6 23925

Interventional clinical trials:

(show top 50) (show all 6966)

# Name Status NCT ID Phase Drugs
1 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
2 Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
3 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Unknown status NCT02570529 Phase 4 Albis®;Placebo
4 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
5 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
6 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
7 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
8 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
9 Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent Unknown status NCT00746538 Phase 4
10 Preoperative Biliary Drainage for Resectable Hilar Cholangiocarcinoma Unknown status NCT00797121 Phase 4
11 A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma Unknown status NCT01758679 Phase 4
12 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
13 Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma Unknown status NCT02729506 Phase 4
14 Prophylactic Antibiotics Before RFA for HCC Unknown status NCT02534961 Phase 4 Cefazolin
15 A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma Unknown status NCT02253511 Phase 4 Cidan capsule
16 A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC Unknown status NCT01997957 Phase 4 S-1
17 Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4 Propranolol
18 Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication Unknown status NCT01894269 Phase 4 Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
19 Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma Unknown status NCT01833299 Phase 4
20 Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma Unknown status NCT01570166 Phase 4
21 Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria Unknown status NCT01570075 Phase 4
22 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4 propranolol
23 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
24 Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma Unknown status NCT01415063 Phase 4
25 Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm Unknown status NCT01351194 Phase 4
26 Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis Unknown status NCT01350206 Phase 4
27 Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00557024 Phase 4
28 TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma Unknown status NCT00556803 Phase 4
29 Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00555334 Phase 4 lamivudine or entecavir
30 Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma Unknown status NCT00554905 Phase 4
31 Conformation of Beta Human Chorionic Gonadotropin During Chemotherapy for Choriocarcinoma Unknown status NCT00294177 Phase 4
32 Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture Unknown status NCT01125865 Phase 4
33 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4 Telbivudine
34 Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
35 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
36 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
37 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
38 Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma Completed NCT00854477 Phase 4 capecitabine
39 A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
40 A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma Completed NCT00097578 Phase 4
41 Clinical Outcomes of Endoscopic Resection for Treating WHYX Lesion Completed NCT01451034 Phase 4
42 Intravenous Iron: Measuring Response in Anemic Surgical Patients Completed NCT02057471 Phase 4 Intravenous ferric carboxymaltose
43 Endoscopic Detection of Dysplasia in Crohn 's Disease Patient Completed NCT01180452 Phase 4
44 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
45 IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia Completed NCT01701310 Phase 4 Ferric carboxymaltose;Ferrous Sulphate
46 Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection Completed NCT00844675 Phase 4 rabeprazole;placebo
47 Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy Completed NCT02025361 Phase 4 intrarectal lidocaine gel;periprostatic nerve blockade
48 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
49 Prospective Randomized Study of SILS Versus CLS for Rectal Cancer Completed NCT01579721 Phase 4
50 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin

Search NIH Clinical Center for Adenocarcinoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: adenocarcinoma

Genetic Tests for Adenocarcinoma

Genetic tests related to Adenocarcinoma:

# Genetic test Affiliating Genes
1 Adenocarcinoma 28

Anatomical Context for Adenocarcinoma

MalaCards organs/tissues related to Adenocarcinoma:

38
Lung, Prostate, Liver, Kidney, Breast, Colon, Pancreas

Publications for Adenocarcinoma

Articles related to Adenocarcinoma:

(show top 50) (show all 15300)
# Title Authors Year
1
International Endocervical Adenocarcinoma Criteria and Classification (IECC): A New Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix. ( 29135516 )
2018
2
Putative lung adenocarcinoma with epidermal growth factor receptor mutation presenting as carcinoma of unknown primary site: A case report. ( 29443782 )
2018
3
Endometrial Adenocarcinoma With Pulmonary Recurrence. ( 29326341 )
2018
4
Vimentin-positive gastric adenocarcinoma arising in a hyperplastic polyp. ( 29417386 )
2018
5
Effects of carvacrol on human fibroblast (WS-1) and gastric adenocarcinoma (AGS) cells in vitro and on Wistar rats in vivo. ( 29442269 )
2018
6
Effect of total number of harvested lymph nodes on survival outcomes after curative resection for gastric adenocarcinoma: findings from an eastern high-volume gastric cancer center. ( 29329569 )
2018
7
Pattern based classification of endocervical adenocarcinoma: a review. ( 29241973 )
2018
8
Effects of long noncoding RNA SPRY4-IT1-mediated EZH2 on the invasion and migration of lung adenocarcinoma. ( 28796375 )
2018
9
Comprehensive Analysis of DNA Methylation and Gene Expression Datasets Identified MMP9 and TWIST1 as Important Pathogenic Genes of Lung Adenocarcinoma. ( 29443542 )
2018
10
Feasibility of EUS-guided Nd:YAG laser ablation of unresectable pancreatic adenocarcinoma. ( 29452076 )
2018
11
Unusual case of left atrial myxoma with gastroesophageal junction adenocarcinoma. ( 29338297 )
2018
12
<i>Celastrus orbiculatus</i> extracts induce apoptosis and inhibit invasion by targeting the maspin gene in human gastric adenocarcinoma cells. ( 29387218 )
2018
13
Chitosan-Cellulose Multifunctional Hydrogel Beads: Design, Characterization and Evaluation of Cytocompatibility with Breast Adenocarcinoma and Osteoblast Cells. ( 29315214 )
2018
14
Martrilin-3 (MATN3) Overexpression in Gastric Adenocarcinoma and its Prognostic Significance. ( 29343680 )
2018
15
A case of urachal villous adenoma with high grade dysplasia focally bordering on adenocarcinoma in situ. ( 29321972 )
2018
16
Intraductal papillary bile duct adenocarcinoma and gastrointestinal stromal tumor in a case of neurofibromatosis type 1. ( 29398874 )
2018
17
BRM270 inhibits cancer stem cell maintenance via microRNA regulation in chemoresistant A549 lung adenocarcinoma cells. ( 29445170 )
2018
18
MiR-7-5p functions as a tumor suppressor by targeting SOX18 in pancreatic ductal adenocarcinoma. ( 29408481 )
2018
19
Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. ( 29094609 )
2018
20
Treatment of long-segment Barrett's adenocarcinoma by complete circular endoscopic submucosal dissection: a case report. ( 29351773 )
2018
21
MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma. ( 29193645 )
2018
22
Metastatic cutaneous apocrine adenocarcinoma responsive to the programmed cell death protein 1A inhibitor pembrolizumab. ( 29237537 )
2018
23
Tumor of the Turkish saddle with endocrine disorders as the first manifestation of gastric adenocarcinoma. ( 29385110 )
2018
24
Alteration of MicroRNA Expression Profiles by Surface-Modified Gold Nanoparticles in Human Lung Adenocarcinoma Cells. ( 29442990 )
2018
25
<i>De novo</i> expression of human polypeptide<i>N</i>-acetylgalactosaminyltransferase 6 (GalNAc-T6) in colon adenocarcinoma inhibits the differentiation of colonic epithelium. ( 29187600 )
2018
26
Treatment of a pediatric patient with MET-amplified signet ring cell adenocarcinoma of the stomach with crizotinib. ( 29380521 )
2018
27
Endonasal endoscopic nasopharyngectomy for the treatment of nasopharyngeal papillary adenocarcinoma: Report of a rare case. ( 29287881 )
2018
28
Chemotherapy of metastatic hepatoid adenocarcinoma: Literature review and two case reports with cisplatin etoposide. ( 29387209 )
2018
29
Hemorrhagic Brain Metastases in a Patient with Anaplastic Lymphoma Kinase (ALK)-Rearranged Invasive Mucinous Adenocarcinoma of the Lung. ( 29371584 )
2018
30
A 65a89gene signature for prognostic prediction in colon adenocarcinoma. ( 29393333 )
2018
31
Investigating the association between African spontaneously fermented dairy products, faecal carriage of Streptococcus infantarius subsp. infantarius and colorectal adenocarcinoma in Kenya. ( 29079186 )
2018
32
A case report of a primary apocrine adenocarcinoma of the eyelid with literature review. ( 29313402 )
2018
33
Diagnosis, clinicopathological characteristics and prognosis of pulmonary mucinous adenocarcinoma. ( 29375717 )
2018
34
Expression of GAEC1 mRNA and protein and its association with clinical and pathological parameters of patients with colorectal adenocarcinoma. ( 29337242 )
2018
35
Primary enteric-type tubulovillous adenocarcinoma arising in the renal pelvis. ( 29446862 )
2018
36
Ovarian conservation is associated with better survival in young patients with T1N0M0 cervical adenocarcinoma: a population-based study. ( 29362924 )
2018
37
Human umbilical cord mesenchymal stem cell-derived extracellular vesicles promote lung adenocarcinoma growth by transferring miR-410. ( 29440630 )
2018
38
<i>Helicobacter pylori</i> eradication treatment and the risk of gastric adenocarcinoma in a Western population. ( 29382776 )
2018
39
Perioperative chemotherapy vs. neoadjuvant chemoradiation inA gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry. ( 29071366 )
2018
40
Amide Proton Transfer MR Imaging of Endometrioid Endometrial Adenocarcinoma: Association with Histologic Grade. ( 29083987 )
2018
41
Nuclear expression of claudin-3 in human colorectal adenocarcinoma cell lines and tissues. ( 29285188 )
2018
42
E-cadherin Loss Accelerates Tumor Progression and Metastasis in a Mouse Model of Lung Adenocarcinoma. ( 29447458 )
2018
43
Clinical outcomes of carbon ion radiotherapy with concurrent chemotherapy for locally advanced uterine cervical adenocarcinoma in a phase 1/2 clinical trial (Protocol 1001). ( 29341491 )
2018
44
Fibrosis-related miRNAs as serum biomarkers for pancreatic ductal adenocarcinoma. ( 29435115 )
2018
45
Pulmonary papillary adenocarcinoma with<i>Aspergillus versicolor</i>infection in a dog. ( 29234587 )
2018
46
Ultrastructure of colorectal adenocarcinoma and peritumoral tissue in untreated patients. ( 29419351 )
2018
47
MID1-PP2A complex functions as new insights in human lung adenocarcinoma. ( 29450633 )
2018
48
Pyruvate kinase type M2 contributes to the development of pancreatic ductal adenocarcinoma by regulating the production of metabolites and reactive oxygen species. ( 29393401 )
2018
49
A phase I trial of the I^-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. ( 29438372 )
2018
50
Quercetin Suppresses CYR61-Mediated Multidrug Resistance in Human Gastric Adenocarcinoma AGS Cells. ( 29364834 )
2018